hos patienter i behandling med entakapon og dopaminagonister (som bromokriptin), selegilin eller amantadin sammenlignet med de, der fik placebo i kombination med de samme stoffer.
patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination.